Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TP-06 in persistent corneal epithelial defects
NCT07886268Phase 2Recruiting
- Sponsor
- Tarsus Pharmaceuticals, Inc.
- Start
- Apr 2026
- Primary completion
- Jul 2028
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in persistent corneal epithelial defect (PED) comparing TP-06 Ophthalmic Solution with Vehicle of TP-06 Ophthalmic Solution (2 arms). Primary endpoint: Complete resolution of corneal fluorescein staining at Day 70. Started Apr 2026; status: recruiting.
02
Drugs
TP-06
03
Conditions
persistent corneal epithelial defect (PED)
Beyond the preview
Go deeper on NCT07886268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07886268.